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Summary and Key Points 
1. Up to 10% of certain cancers are familial. 
2. Cancer syndromes are inherited in an autosomal dominant 
fashion. 
3. Inheritance of a familial gene mutation greatly increases the risk of 
cancer. 
4. Identification of cancer syndromes and their genes allows for 
increased surveillance and/or tailored treatments. 
Introduction 
While the majority of cancers are not inherited, there are a number of 
well described collections of cancers that occur within families. These 
cancer syndromes were initially identified based on observation of family 
histories and subsequently the molecular mechanisms have been 
elucidated. This chapter is intended to allow the reader to recognize 
when a pattern of cancers occurs in an individual or their family, and to 
generate an investigation into potential cancer syndromes. With the 
rapidly expanding understanding of the molecular basis of cancers at the 
cellular and constitutional levels, appropriate preventive care may be 
offered and tailored treatment holds great promise. 
Important Concepts 
All cancer is genetic on the cellular level. All tumors, inherited or 
sporadic, arise from deregulation of genetic instructions intended to keep 
cells growing and functioning normally. At the cellular level this occurs in 
a recessive pattern, meaning that somatic damage must occur to both 
the paternally and maternally inherited copy of the regulatory gene. 
Cancer predisposition, or the inheritance of a germline mutation 
increasing likelihood of cancer occurrence, is inherited in a dominant 
fashion. This is illustrated through Knudson’s two-hit hypothesis1 (Movie
1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Movie 1. Kudson’s Two-Hit Hypothesis. Movie courtesy of University of 
Massachusetts Medical School, Department of Pediatrics. 
Keep in mind that there are genetic tests that look for somatic genetic 
changes. These somatic changes may inform treatments such as 
effective chemotherapies. That is why this testing is performed 
specifically on a tumor. However, genetic testing for cancer 
predisposition is always performed looking for germline inherited 
mutations, which is why it is often done on blood samples. 
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Key features in a family or individual that raise the suspicion for an 
inherited cancer syndrome include:4 
• Early onset of cancer 
• Multiple primary tumors in the same person (not related to prior 
treatment) 
• Multiple affected family members 
• Occurrence of cancer in multiple generations, clustering of 
related cancers 
• Ashkenazi Jewish heritage (specific for BRCA) 
Early onset cancer is generally defined as diagnosis at or below the 
age of 50. The pedigree below (Figure 1) depicts a sample family history 
that could be applied to any of the following cancer syndromes. 
 
Figure 1. Sample cancer syndrome family history pedigree. University of 
Massachusetts Medical School, Department of Pediatrics. 
The following specific cancer syndromes will be discussed: BRCA, Lynch 
syndrome, and FAP. Evidence based management guidelines for these 
conditions are maintained by the National Comprehensive Cancer 
Network. This group makes up a representative sample of numerous 
familial cancers, some of which are quite rare. 
Hereditary Breast and Ovarian Cancer 
BRCA1 & BRCA2 
These are tumor suppressor genes which function in the DNA repair 
pathway.2 In the general population, the likelihood of a BRCA mutation is 
1 in 500. Within the Ashkenazi Jewish population there are 3 founder 
mutations, which increase the risk to 1 in 40. Inheritance of a mutation in 
one of these genes increases the risk for the following cancers (in 
decreasing order): breast (up to 87% by age 70), ovarian (up to 40% by 
70), prostate (20%), pancreatic (7%) and melanoma (specific to BRCA2 
mutations). The risk of male breast cancer is also increased to 
approximately 8%. Early and frequent screenings, as well as select 
preventive treatments, are available to mutation-positive individuals, the 
details of which are beyond the scope of this chapter. 
Colon Cancer 
Lynch Syndrome 
Also called Hereditary Nonpolyposis Colorectal Cancer (HNPCC), this 
disorder is caused by mutations in one of several genes involved in DNA 
mismatch repair. The genes, listed in order of frequency, are MLH1, 
MSH2, MSH6, EPCAM and PMS2. Mutations in one of these genes, 
most often MLH1 and MSH2, account for 1%-3% of all colon cancers 
and ~1% of all endometrial cancers. Colorectal tumors excised from 
patients with Lynch syndrome exhibit microsatellite instability (MSI), and 
immunohistochemistry staining of the tumor can facilitate targeted testing 
for these genes. Individuals who have inherited one of these gene 
mutations are at increased risk for cancer of the colon (80% by age 70), 
endometrium (60%), stomach (13%), ovary (9%-12%), biliary tract (2%-
18%), urinary tract (5%-10%) and brain (1%-3%). Screening modalities 
are available for colon cancer and prophylactic hysterectomy or 
oophorectomy may be offered.3 
It should be noted that the moniker “nonpolyposis” is misleading, since 
affected individuals have polyps prior to colorectal cancer; the term was 
used to distinguish Lynch syndrome from Familial Adenomatous 
Polyposis (FAP). Several sets of guidelines have been used to determine 
the likelihood of Lynch syndrome in a family or individual, but recent 
studies argue for broader screening by use of MSI/IHC testing in tumor 
cells. 
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Familial Adenomatous Polyposis 
While rare, accounting for 0.5%-1% of all colon cancers, FAP 
demonstrates remarkable penetrance within families. Virtually 100% of 
individuals with FAP will develop colon cancer unless treated, with 
diagnosis at the mean age of 39 and with onset of polyps in childhood. 
Polyps are extensive, numbering in the 100s to 1000s.  FAP is caused 
by mutations of the APC gene, the normal function of which appears to 
be a tumor suppressor with an additional role in colonic cell migration. In 
addition to colon cancer, affected individuals are at an increased lifetime 
risk for cancer of the small bowel (4-12%), pancreas (2%), thyroid (1%-
2%), liver (~1%) and brain (<1%).  Attenuated FAP is characterized by 
fewer colonic polyps and later onset of cancer (still with significant risk) 
thought to be correlated to specific APC mutations. Non-cancer related 
findings in FAP include congenital hypertrophy of the retinal epithelium 
(CHRPE), osteomas, dental anomalies, epidermoid cysts, lipomas, and 
desmoid tumors. Screening for polyps begins between 10-12 years of 
age, and colectomy is typically performed after the development of 
adenomas. 
Assessment & Evaluation of Genetic Risk 
With improvements in technology, the cost to sequence a gene has 
rapidly decreased. This has led to the introduction of multi-gene panels. 
For what it previously cost to sequence just BRCA1 and BRCA2, many 
laboratories are performing analysis of 20-40 genes at once. This new 
approach increases clinical sensitivity (identifies more mutation carriers), 
but increases the likelihood of identifying genetic changes of uncertain 
clinical significance or mutations for which appropriate medical 
management guidelines do not exist. For this reason, it is essential that 
the benefits, limitations and risks of genetic testing be discussed with a 
knowledgeable professional. 
When a family or individual presents with a history that indicates a 
potential inherited cancer syndrome, genetic counseling is strongly 
recommended. There may be social, financial and emotional 
consequences to pursuing definitive genetic testing. In order to locate a 
genetics professional in your area, see http://www.nsgc.org/ 
 
Thought Questions 
1. A 42 year old woman discovers she has a 1 cm breast lump that is 
cancerous. Standard surgical options can include lumpectomy 
(removing only the tumor and preserving the breast) or mastectomy 
(removing the entire breast). She asks to be tested for the presence 
of a mutation in BRCA1 or BRCA2. How might the results of the test 
affect her choice of surgery? 
Your answer: 
 
 
 
 
 
Expert Answer 
 
 
 
 
2. What are the advantages to a patient of knowing members of their 
family carry a familial cancer syndrome gene? 
Your answer: 
 
 
 
 
Expert Answer 
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3. What are the disadvantages to a patient of knowing members of their 
family carry a familial cancer syndrome gene? 
Your answer: 
 
 
 
 
 
 
Expert Answer 
 
 
 
 
 
 
4. Why would a physician want to know if a patient carries a familial 
cancer syndrome gene? 
Your answer: 
 
 
 
 
Expert Answer 
 
 
 
 
 
 
5. Why would a patient from an affected family want to know (or not 
know) if they personally carry a familial cancer syndrome gene? 
Your answer: 
 
 
 
 
 
Expert Answer 
 
 
 
 
Glossary 
Autosomal- Relating to any chromosome that is not a sex (X or Y) 
chromosome 
Germline- relating to sperm or egg cells, germline changes when 
inherited are found every cell of the body 
Hit- Mutation 
Inherited cancer- occur as part of a cancer predisposition syndrome 
Knudson’s two-hit hypothesis- The concept that mutations (hits) in two 
alleles are necessary for inactivation of a tumor suppressor gene 
Somatic- relating to specific cells of the body (such as breast cells or 
colon cells), somatic changes are not passed on to children 
Sporadic cancer- occur due to accumulated somatic genetic changes, 
over time, typically later in life 
 
  
Familial Cancer Syndromes 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (11 February 2016) 
5 
References 
1. Knudson AG Jr. Mutation and cancer: statistical study of 
retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820-3. 
2. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in 
Pten dose determine cancer susceptibility. Nat Genet. 
2010;42(5):454-8. 
3. EGAPP Working Group. Recommendations from the EGAPP 
Working Group: genetic testing strategies in newly diagnosed 
individuals with colorectal cancer aimed at reducing morbidity and 
mortality from Lynch syndrome in relatives. Genetics in Medicine. 
2009;11(1):35-41. 
4. Lindor NM, McMaster ML, Lindor CJ, Greene MH; National Cancer 
Institute, Division of Cancer Prevention, Community Oncology and 
Prevention Trials Research Group. Concise handbook of familial 
cancer susceptibility syndromes – second edition. J Natl Cancer Inst 
Monogr. 2008;(38):1-93. 
